Você está na página 1de 3

-

634.32+615.015.2

.. 1, .. 2
1
(Lawson Health Research Institute), ,
2
, ,



- -
. ,
.
, -, . -
. CYP3A4,
.
. ,
-
.
, .
,
. , , ,
.
. -
-
.
: , , , , .

2009; NieminenT.H. etal., 2010).


,
,
(KanazawaS. etal., 2001; Mahgoub A.A., 2002; OkuraT. etal., 2008; .
SeidegrdJ. etal., 2009; Nieminen T.H. etal., 2010; BaileyD.G. etal., (70%),
2013
). CYP3A4 peros.
: (),
(
MalhotraS. etal., 2001; Guo L.Q. etal., 2007
). ,
(, ,
) (BaileyD.G. etal., 2013). ,
(, ) (BaileyD.G. etal., 2013).
.
, .
(200250 )
P450, CYP3A4,
. . , ,
, .
CYP3A4 3-
; .
CYP3A4 . 250 3
6
, 5- .
.
, .
, 4
(KanazawaS. etal., 2001; BaileyD.G. etal., ; 24
2013). 25% 50%
(LundahlJ. etal.,
1995; TakanagaH. etal., 2000; BaileyD.G. etal., 2013).
. , ,
(Duchar (
DresserG.K. etal., 2000
).
meM.P. etal., 1995; LundahlJ. etal., 1995). ,
, CYP3A4.
, , ,
D.G.Bailey (2013). , .
, -,
, , , ,
, , (
-), , (
GoldbartA. etal., 2000; HermansK. etal., 2003; DreierJ.P., En
, (KanazawaS. etal., dresM., 2004; KarchA.M., 2004; GrandeL.A. etal., 2009; PillaiU.
2001; MahgoubA.A., 2002; OkuraT. etal., 2008; SeidegrdJ. etal., etal., 2009; AgostiS. etal., 2012
).

. . , 2017, 16 [ ] | WWW.UMJ.COM.UA 1
-
,
(DresserG.K. etal., .
2000; BaileyD.G. etal., 2013). , , ,
, ,
. .

, .
. ,
,
.
QT (vonWoedtkeT. etal., 1999; HeggersJ.P. etal., 2002;
, CvetniZ., Vladimir-KnezeviS., 2004; AdukwuE.C. etal., 2012).

; ,
(torsades de pointes). . ;

.
, () ;
. (JourdanP.S. etal., 1985).
: , -
. (MazokopakisE.E., 2008; BaileyD.G. etal., ; ,
2013
). (
) .
. , , ,
, .
,
. .
,
, .

.

. .
, ,
.

.

. .. , ..
, . -
, .
,
(DucharmeM.P. etal., 1995; .
HollanderA.A. etal., 1995; SridharanK., SivaramakrishnanG., 2016). , , . -
. -
,
CYP3A4, -
, .
.
CYP3A4. , -
,
(El-LakkanyN.M. etal., . -
2004). ,
(, .
) (
MahgoubA.A., 2002; OkuraT. etal., 2008; Niemin -
enT.H. etal., 2010
). , . ,
(Dasgupta A. etal., 2008; Qinna N.A. etal., 2016). , , .

. . -

(, )
.
(VarisT. etal., 2000; SeidegrdJ. etal.,
2009), : , , ,
. , .
(HollanderA.A. etal.,
1995). Grapefruit-medication interactions
: D.G. Bailey, S.V. Jargin
;
(HollanderA.A. etal., 1995; KanazawaS. Summary. This mini-review discusses key scientific concepts and clinical
implications of grapefruit-drug interactions. Grapefruit and certain re-
etal., 2001). ,
lated citrus fruits (Seville orange, pomelo, lime) are foods considered to

be healthful but having the potential for a pharmacokinetic interaction
(JungU.J. etal., 2004; PunithavathiV.R. etal., causing enhanced oral bioavailability of certain drugs. The active con-
2008; MahmoudA.M. etal., 2012; XuluS., Oroma OwiraP.M., 2012; stituents are most likely furanocoumarins. Varieties of sweet oranges
AlamM.A. etal., 2014; ChudnovskiyR. etal., 2014; MurungaA.N. etal., neither contain furanocoumarins nor produce this interaction. The inter-
2016; SirovinaD. etal., 2016
). action involves irreversible inactivation of the enzyme CYP3A4involved
in the metabolism of many drugs. The key issues are adverse effects
. occurring in routine clinical practice; some of them are discussed here.

2 . . , 2017, 16 [ ] | WWW.UMJ.COM.UA
-
While grapefruit-drug interactions are generally considered to be negative Kanazawa S., Ohkubo T., Sugawara K. (2001) The effects of grapefruit
occurrences to be avoided, there has been consideration to use this in- juice on the pharmacokinetics of erythromycin. Eur. J. Clin. Pharmacol., 56(11):
teraction to achieve beneficial therapeutic goals i.e. lowering of drug 799803.
dosages. Unfortunately, the effect has been highly variable among indi- Karch A.M. (2004) The grapefruit challenge: the juice inhibits a crucial enzyme,
viduals and studies. Development of a standard drug on the basis of fu- with possibly fatal consequences. Am. J. Nurs., 104(12): 3335.
ranocoumarins may be a solution. In conclusion, grapefruit and certain Lundahl J., Regrdh C.G., Edgar B., Johnsson G. (1995) Relationship
other citrus fruits have the potential for an interaction causing enhanced between time of intake of grapefruit juice and its effect on pharmacokinetics
bioavailability of some oral drugs. This action carries the risk of adverse andpharmacodynamics of felodipine in healthy subjects. Eur. J. Clin. Pharmacol.,
events from excessive effect, particularly for drugs with overdose toxici- 49(12): 6167.
ties. This necessitates an understanding of this interaction and the ap- Mahgoub A.A. (2002) Grapefruit juice potentiates the anti-inflammatory ef-
plication of such in the safe and effective use of drugs in general practice. fects of diclofenac on the carrageenan-induced rats paw oedema. Pharmacol. Res.,
Key words: grapefruit, pharmacotherapy, pharmacokinetics, drug inter- 45(1): 14.
action, nutrition. Mahmoud A.M., Ashour M.B., Abdel-Moneim A., Ahmed O.M. (2012)
Hesperidin and naringin attenuate hyperglycemia-mediated oxidative stress and
proinflammatory cytokine production in high fat fed/streptozotocin-induced type2
Adukwu E.C., Allen S.C., Phillips C.A. (2012) The anti-biofilm activity diabetic rats. J. Diabetes Complications, 26(6): 483490.
oflemongrass (Cymbopogon flexuosus) and grapefruit (Citrus paradisi) essential oils Malhotra S., Bailey D.G., Paine M.F., Watkins P.B. (2001) Seville orange
against five strains of Staphylococcus aureus. J. Appl. Microbiol., 113(5): 12171227. juice-felodipine interaction: comparison with dilute grapefruit juice and involvement
Agosti S., Casalino L., Bertero G. et al. (2012) A dangerous fruit juice. of furocoumarins. Clin. Pharmacol. Ther., 69(1): 1423.
Am. J. Emerg. Med., 30(1): 248.e5248.e8. Mazokopakis E.E. (2008) Unusual causes of rhabdomyolysis. Intern. Med.J.,
Alam M.A., Subhan N., Rahman M.M. et al. (2014) Effect of citrus flavo- 38(5): 364367.
noids, naringin and naringenin, on metabolic syndrome and their mechanisms Murunga A.N., Miruka D.O., Driver C. et al. (2016) Grapefruit derived
ofaction. Adv. Nutr., 5(4): 404417. flavonoid naringin improves ketoacidosis and lipid peroxidation in type1 diabetes
Bailey D.G., Dresser G., Arnold J.M. (2013) Grapefruit-medication inter- rat model. PLoS One, 11(4): e0153241.
actions: forbidden fruit or avoidable consequences? CMAJ, 185(4): 309316. Nieminen T.H., Hagelberg N.M., Saari T.I. et al. (2010) Grapefruit juice
Chudnovskiy R., Thompson A., Tharp K. et al. (2014) Consumption enhances the exposure to oral oxycodone. Basic Clin. Pharmacol. Toxicol., 107(4):
ofclarified grapefruit juice ameliorates high-fat diet induced insulin resistance and 782788.
weight gain in mice. PLoS One, 9(10): e108408. Okura T., Ozawa T., Ito Y. et al. (2008) Enhancement by grapefruit juice
Cvetni Z., Vladimir-Knezevi S. (2004) Antimicrobial activity of grapefruit ofmorphine antinociception. Biol. Pharm. Bull., 31(12): 23382341.
seed and pulp ethanolic extract. Acta Pharm., 54(3): 243250. Pillai U., Muzaffar J., Sen S., Yancey A. (2009) Grapefruit juice andvera-
Dasgupta A., Reyes M.A., Risin S.A., Actor J.K. (2008) Interaction pamil: a toxic cocktail. South Med. J., 102(3): 308309.
ofwhite and pink grapefruit juice with acetaminophen (paracetamol) in vivo in mice. Punithavathi V.R., Anuthama R., Prince P.S. (2008) Combined treatment
J. Med. Food, 11(4): 795798. with naringin and vitamin C ameliorates streptozotocin-induced diabetes in male
Dreier J.P., Endres M. (2004) Statin-associated rhabdomyolysis triggered Wistar rats. J. Appl. Toxicol., 28(6): 806813.
by grapefruit consumption. Neurology, 62(4): 670. Qinna N.A., Ismail O.A., Alhussainy T.M. et al. (2016) Evidence of reduced
Dresser G.K., Bailey D.G., Carruthers S.G. (2000) Grapefruit juice oral bioavailability of paracetamol in rats following multiple ingestion of grapefruit
felodipine interaction in the elderly. Clin. Pharmacol. Ther., 68(1): 2834. juice. Eur. J. Drug Metab. Pharmacokinet., 41(2): 187195.
Ducharme M.P., Warbasse L.H., Edwards D.J. (1995) Disposition ofin- Seidegrd J., Randvall G., Nyberg L., Borg O. (2009) Grapefruit juice
travenous and oral cyclosporine after administration with grapefruit juice. Clin. interaction with oral budesonide: equal effect on immediate-release and delayed-
Pharmacol. Ther., 57(5): 485491. release formulations. Pharmazie, 64(7): 461465.
El-Lakkany N.M., Seif el-Din S.H., Badawy A.A., Ebeid F.A. (2004) Sridharan K., Sivaramakrishnan G. (2016) Interaction of citrus juices
Effect of artemether alone and in combination with grapefruit juice on hepatic drug- withcyclosporine: systematic review and meta-analysis. Eur. J. Drug Metab. Phar-
metabolising enzymes and biochemical aspects in experimental Schistosoma macokinet., 41(6): 665673.
mansoni. Int. J. Parasitol., 34(12): 14051412. Sirovina D., Oroli N., Gregorovi G., Koni M.Z. (2016) Naringenin
Goldbart A., Press J., Sofer S., Kapelushnik J. (2000) Near fatal acute ameliorates pathological changes in liver and kidney of diabetic mice: a preliminary
colchicine intoxication in a child. A case report. Eur. J. Pediatr., 159(12): 895897. study. Arh. Hig. Rada Toksikol., 67(1): 1924.
Grande L.A., Mendez R.D., Krug R.T., Verschuyl E.J. (2009) Attention Takanaga H., Ohnishi A., Murakami H. et al. (2000) Relationship between
grapefruit! Lancet, 373(9670): 1222. time after intake of grapefruit juice and the effect on pharmacokinetics and phar-
Guo L.Q., Chen Q.Y., Wang X. et al. (2007) Different roles of pummelo macodynamics of nisoldipine in healthy subjects. Clin. Pharmacol. Ther., 67(3):
furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action 201214.
of felodipine. Curr. Drug Metab., 8(6): 623630. Varis T., Kivist K.T., Neuvonen P.J. (2000) Grapefruit juice can increase
Heggers J.P., Cottingham J., Gusman J. et al. (2002) The effectiveness the plasma concentrations of oral methylprednisolone. Eur. J. Clin. Pharmacol.,
ofprocessed grapefruit-seed extract as an antibacterial agent: II. Mechanism ofac- 56(67): 489493.
tion and in vitro toxicity. J. Altern. Complement. Med., 8(3): 333340. von Woedtke T., Schlter B., Pflegel P. et al. (1999) Aspects of the an-
Hermans K., Stockman D., van den Branden F. (2003) Grapefruit and timicrobial efficacy of grapefruit seed extract and its relation to preservative sub-
tonic: a deadly combination in a patient with the long QT syndrome. Am. J. Med., stances contained. Pharmazie, 54(6): 452456.
114(6): 511512. Xulu S., Oroma Owira P.M. (2012) Naringin ameliorates atherogenic dys-
Hollander A.A., van Rooij J., Lentjes G.W. et al. (1995) The effect lipidemia but not hyperglycemia in rats with type 1 diabetes. J. Cardiovasc. Phar-
ofgrapefruit juice on cyclosporine and prednisone metabolism in transplant patients. macol., 59(2): 133141.
Clin. Pharmacol. Ther., 57(3): 318324.
Jourdan P.S., McIntosh C.A., Mansell R.L. (1985) Naringin Levels inCit-
rus Tissues: II. Quantitative Distribution of Naringin in Citrus paradisi MacFad. Plant :
Physiol., 77(4): 903908.
Jung U.J., Lee M.K., Jeong K.S., Choi M.S. (2004) The hypoglycemic 115184, Moca, . , 6, . 82
effects of hesperidin and naringin are partly mediated by hepatic glucose-regulat- E-mail: sjargin@mail.ru
ing enzymes in C57BL/KsJ-db/db mice. J. Nutr., 134(10): 24992503. 05.02.2017

. . , 2017, 16 [ ] | WWW.UMJ.COM.UA 3